Cambridge Innovation Capital — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis.
BiotechMedical Devices
Mark Pepys(Co-founder; Emeritus Professor of Medicine at UCL)Gregory Winter(Co-founder; Nobel Laureate)Daniel Christ(Co-founder; Professor, Faculty of Medicine, UNSW)
Co-investorsFrazier Life SciencesQiming Venture PartnersF-Prime CapitalSR One Capital Management
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Trent Ai
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.